ArticleJournal of thoracic disease2018
Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?
Anthonie J van der Wekken et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it